Maxim Group maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) and raised its price target to $32.00 (from $26.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE